Alameda, CA.—(BUSINESS WIRE)—March 22, 2007 Advanced Cell Technology, Inc.’s (OTCBB: ACTC) Michael D. West, Ph.D., President and Chief Scientific Officer, will discuss “Strategies for the Accelerated Development of Therapeutics from hES Cells” at the 3rd Annual Stem Cell Research and Therapeutics Summit hosted by GTCbio Friday March 23, 2007 at 2:30 PM PT in California. The conference will be held at the San Diego Marriott La Jolla Conference Center and will run from March 22-23, 2007.
In his discussion, Dr. West will discuss the company’s ACTCellerate technology and the heart muscle progenitor SK17 that is being studied under a recently funded CIRM grant.
Dr. West’s presentation will be available for viewing at the Company’s web site http://www.advancedcell.com/conference-presentations/.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the Annual Report on Form 10-KSB for the year ended December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
The Investor Relations Group
Investors: James Carbonara, 212-825-3210
Media: Bill Douglass, 212-825-3210
Source: Advanced Cell Technology, Inc.
James Carbonara
212-825-3210